HC Wainwright & Co. Maintains Neutral on Co-Diagnostics, Lowers Price Target to $2.5
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen maintains a Neutral rating on Co-Diagnostics (CODX) and lowers the price target from $3 to $2.5.
March 15, 2024 | 10:50 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
HC Wainwright & Co. maintains a Neutral stance on Co-Diagnostics, but reduces the price target from $3 to $2.5.
The reduction in price target by HC Wainwright & Co. suggests a less optimistic outlook on Co-Diagnostics' stock value in the short term, potentially leading to negative investor sentiment and a decrease in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100